Pneumonia (CAP, HAP & VAP) Flashcards

1
Q

Define “pneumonia”.

A

Lower respiratory tract infection of the lung parenchyma

Due to abnormal proliferation of microbial pathogens in alveolar level (normally sterile), commonly via bacteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Briefly describe the pathogenesis of pneumonia.

A

Bacteria enter the lower respiratory tract through various MOA:

  • Aspiration of oropharyngeal secretions
  • Inhalation of infected aerosolised droplets containing bacteria
  • Hematogenous spreading (i.e. bacteremia) from extrapulmonary source
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some signs and symptoms displayed by pt with pneumonia?

A

Localised: Cough, chest pain, SOB/dyspnea, hypoxia
Systemic:
- Fever > 38 deg C, chills
- Tachypnea, tachycardia, hypotension
- Leukocytosis (i.e. elevated WBC)
- Malaise, anorexia, nausea, changes in mental status (esp. elderly pt.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the clinical tests available that may aid in the diagnosis of pneumonia?

A

1) Physical examination
- Diminished breath sounds over the affected area of lungs using a stethoscope
- Inspiratory crackles during lung expansion
2) Radiological findings
- Chest x-ray (more commonly used; less expensive) > CT scan (used if Tx failure or immunocompromised)
- Observed for new infiltrates or dense consolidations
3) Laboratory findings (e.g. C-reactive protein, procalcitonin)
- Non-specific & limited discriminatory potential when used alone (e.g. CKD pt. has elevated [procalcitonin])
- Not recommended for routine use to guide Abx initiation or continuation
4) Respiratory cultures
- Sputum is most readily available, but low yields due to frequent contamination by oropharyngeal secretions; quality sample must include > 10 neutrophils & < 25 epithelial cells per low-power field
- Lower respiratory tract samples are preferred due to less contamination risk but require invasive sampling (e.g. bronchoalveolar lavage)
5) Blood culture
- Rule out bacteremia in hospitalized pt.
6) Urinary antigen tests
- Specific to S. pneumonia & Legionella pneumophilia serogroup 1
- Not routinely used; indicate exposure to respective antigens & NOT necessarily infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How is pneumonia clinically diagnosed?

A

Look for pulmonary signs & smx during clinical examination & correlate to chest radiological findings to establish presence of pneumonia!
Many cases of pneumonia are empirically Tx; Abx is initiated upon clinical suspicion before pathogen identification (due to difficulties obtaining cultures).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Briefly explain the classification of pneumonia.

A

Community-acquired pneumonia (CAP):
Onset in community or < 48h after hospital admission

Healthcare-associated pneumonia (HAP):
Onset >= 48h after hospital admission

Ventilatory-acquired pneumonia (VAP):
Onset >= 48h after mechanical ventilation

Nosocomial pneumonia includes both HAP & VAP.
- Healthcare-associated pneumonia (HCAP) is obsolete

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

List the risk factors associated with pneumonia.

A
> 65 y/o
Previous hospitalisation for CAP
Smoking 
Selected comorbidities such as:
- COPD, DM, HF, cancer & immunocompromised
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are some preventive measures that can be taken to minimise the risk of pneumonia?

A

Smoking cessation
Vaccinations (influenza & pneumococcal)
- Post-influenza bacterial pneumonia can be a serious complication
- PCV is highly effective due to the prevalence of S. pneumoniae as a common causative pathogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the microbiology of CAP.

A

Outpatient:

  • S. pneumoniae
  • H. influenzae
  • Atypicals: Mycoplasma pneumoniae, Chlamydophilia pneumoniae

Inpatient (Non-Severe): Aforementioned + Legionella pneumophilia

Inpatient (Severe): Aforementioned + S. aureus + other gram-negative bacilli

  • Klebsiella pneumoniae
  • Burkholderia pseudomallei
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which microorganism is specifically found as part of the microbiology of severe inpatient CAP in Singapore?

A

Burkholderia pseudomallei

  • unique pathogen that causes melioidosis (severe pneumonia)
  • endemic in Asia & thus not mentioned in IDSA guidelines
  • important implication in empiric Abx selection in inpatient settings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are some consideration in the general Tx approach to CAP?

A

Severity of CAP pt’s clinical presentation determines:

  • Location of treatment (outpatient vs general ward vs ICU)
  • Coverage against specific pathogens
  • Empiric Abx regimen
  • ROA (PO vs IV)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the two validated scoring systems that help with the prediction of CAP pt’s mortality & Tx outcomes.

A

1) Pneumonia Severity Index (PSI)
- Class I & II: outpatients
- Class III: short-term hospitalisation or observation
- Class IV & V: inpatients
- Complexity limits use in clinical settings as 20 variables are used to stratify

2) CURB-65
+1 Confusion
+1 Urea > 7 mmol/L
+1 Respiratory Rate >= 30 breaths per min
+1 Blood pressure (SBP < 90 mmHG or DBP <= 60 mmHg)
+1 Age >= 65 y/o
- 0-1 are outpatients; 2 is inpatient; 3-5 is inpatient w/ ICU consideration
- Easy to use with 5 readily available parameters to stratify into 3 mortality risk classes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Based on IDSA guidelines, what is considered severe CAP?

A

> = 1 major criteria OR >= 3 minor criteria

Major: 
- mechanical ventilation
- septic shock requiring vasoactive medications (to counteract hypotension)
Minor:
- Confusion / disorientation
- Uremia (urea > 7 mmol/L)
- RR >= 30 breaths/min
- Hypotension requiring aggressive fluid resuscitation
- PaO2/FiO2 <= 250 (marker of hypoxia)
- Multilobar infiltrates
- Hypothermia (core temp < 36 deg C)
- Leukopenia (WBC < 4 x 10^9 /L)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which patient populations are identified to require atypical coverage when treating pt with CAP in outpatient settings?

A
Chronic heart, lung, kidney, liver diseases
Diabetes mellitus
Alcoholism 
Malignancy
Asplenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

WH is a 48-year-old female with a past medical history significant for heartburn, hypothyroidism and migraine. She presented to the emergency department with a 2-day history of cough and shortness of breath. She was diagnosed with pneumonia but her doctor felt that she was well enough to return home. WH has never been admitted to the hospital, has normal renal function and has no known drug allergies. Recommend the most appropriate Abx regimen to treat WH’s infection.

A

Amoxicillin PO 1g TDS x at least 5 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

YH is a 45-year-old female with a past medical history significant for T2DM. She presented to the emergency department with a 2-day history of cough and shortness of breath. She was diagnosed with pneumonia but her doctor felt that she was well enough to return home. WH has never been admitted to the hospital, has normal renal function and has no known drug allergies. Recommend the most appropriate Abx regimen to treat YH’s infection.

A

Beta-lactams + macrolides/doxycycline as standard regimen PO for at least 5 days

Beta-lactams:

1) Amoxicillin/clavulanate 625 mg TDS OR 2g BD or
2) Cefuroxime 500 mg BD
- to cover for beta-lactamase strains for H. influenzae

and Macrolides/Doxycycline:

1) Azithromycin 500 mg OD or
2) Clarithromycin 500 mg BD or
3) Doxycycline 100mg BD
- to cover for atypical (Mycoplasma & Chlamydia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ZH is a 60-year-old male with a past medical history significant for osteoporosis. He presented to the emergency department with a 2-day history of cough and shortness of breath. He was diagnosed with pneumonia but his doctor felt that he was well enough to return home. ZH has never been admitted to the hospital, has normal renal function and has a known drug allergy to penicillins. Recommend the most appropriate Abx regimen to treat ZH’s infection.

A

Levofloxacin PO 750mg OD x at least 5 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

For a patient diagnosed with outpatient CAP with a known penicillin allergy, PO ciprofloxacin 500mg BD for at least 5 days is an appropriate Tx option. True or false?

A

False! Ciprofloxacin is NOT a respiratory fluoroquinolone, i.e. does not have activity against gram-positive S. pneumoniae!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Why is erythromycin not recommended as a treatment option in addition to beta-lactams when treating an outpatient CAP patient with CKD?

A

Older macrolide with greater GI side effects, thus newer macrolides such as clarithromycin or azithromycin are recommended instead.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

A 68 y/o male with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. He was diagnosed with CAP and was admitted to the general medicine ward for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 22
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 5.4 mmol/L
Allergies: no known drug allergies
Previous hospitalization: none
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

IV Beta-lactams + PO macrolides/doxycycline as standard regimen for at least 5 days (subjected to step-down Tx)

IV Beta-lactams:

1) Amoxicillin/clavulanate 1.2g q8h or
2) Ceftriaxone 1-2g q24h

and PO Macrolides/Doxycycline:

1) Azithromycin 500 mg OD or
2) Clarithromycin 500 mg BD or
3) Doxycycline 100mg BD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

A 68 y/o male with PMH of T2DM presented to A&E with cough, chest pain, fever, nausea & vomiting and confusion x 2 days. He was diagnosed with CAP and would be admitted to the general medicine ward for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 22
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 5.4 mmol/L
Allergies: no known drug allergies
Previous hospitalization: none
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

IV Beta-lactams + IV macrolides/doxycycline as standard regimen for at least 5 days (subjected to step-down Tx)

IV Beta-lactams:

1) Amoxicillin/clavulanate 1.2g q8h or
2) Ceftriaxone 1-2g q24h

and IV Macrolides/Doxycycline (due to N/V):

1) Azithromycin 500 mg q24h or
2) Clarithromycin 500 mg q12h or
3) Doxycycline 100mg BD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

A 68 y/o male with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. He was diagnosed with CAP and would be admitted to the general medicine ward for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 22
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 5.4 mmol/L
Allergies: penicillin (hives)
Previous hospitalization: none
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

Levofloxacin IV 750mg q24h for at least 5 days (subjected to step-down Tx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

A 63 y/o male with PMH of T2DM presented to A&E with cough, chest pain, fever, nausea & vomiting and confusion x 2 days. He was diagnosed with CAP and would be admitted to the hospital for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 31
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 7.4 mmol/L
Allergies: no known drug allergies
Previous hospitalization: 1 month ago; received ceftriaxone IV for UTI
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

IV Beta-lactams + IV macrolides/doxycycline + IV ceftazidime as standard regimen for at least 5 days (subjected to step-down Tx)

IV Beta-lactams:

1) Amoxicillin/clavulanate 1.2g q8h or
2) Ceftriaxone 1-2g q24h

and IV Macrolides/Doxycycline (due to N/V):

1) Azithromycin 500 mg q24h or
2) Clarithromycin 500 mg q12h or
3) Doxycycline 100mg BD

PLUS IV ceftazidime 2g q8h for specific coverage against Burkholderia pseudomallei

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

A 62 y/o male with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. He was diagnosed with CAP and would be admitted to the hospital for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 31
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 7.4 mmol/L
Allergies: penicillin (rash)
Previous hospitalization: 1 month ago; received ceftriaxone IV for UTI
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

Levofloxacin IV 750mg q24h for at least 5 days (subjected to step-down Tx) due to penicillin allergy
- If penicillin allergy is mild & possible to challenge, IV cefepime 2g q8h may be used.

PLUS IV ceftazidime 2g q8h for specific coverage against Burkholderia pseudomallei

  • possible to tolerate 3rd gen cephalosporins & incidence of cross-reactivity is low for ceftazidime for mild penicillin allergy
  • however, for severe penicillin allergy, can omit ceftazidime as there is no other effective alternative to target B. pseudomallei
  • need to monitor closely & follow up with cultures to inform our Abx Tx further
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

List the additional antibacterial coverage that should be considered when treating CAP pt in an inpatient setting.

A

Anaerobic coverage
MRSA coverage
P. aeruginosa coverage

26
Q

Under what conditions should additional anaerobic coverage in the Tx of an inpatient CAP pt?

A

Radiological findings show either lung abscess (i.e. pus collection in lung parenchyma) or empyema (i.e. pus collection in pleural space)

27
Q

A 65 y/o female with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. She was diagnosed with CAP and would be admitted to the general medicine ward for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 22
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 5.4 mmol/L
Allergies: penicillin (hives)
Previous hospitalization: none
Chest XR: lung abscess in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

Levofloxacin IV 750mg q24h for at least 5 days (subjected to step-down Tx)

PLUS anaerobic coverage:
1) Clindamycin PO 300mg QDS or IV 600mg q8h OR
2) Metronidazole PO/IV 500mg TDS
since lung abscess is observed in CXR

28
Q

Under what conditions should additional MRSA coverage in the Tx of an inpatient CAP pt?

A

1) Prior respiratory isolation of MRSA in 1 year
2) For severe CAP ONLY, hospitalisation & received IV Abx w/in last 90 days for ANY indications
3) For severe CAP ONLY, locally validated risk factors

29
Q

A 62 y/o male with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. He was diagnosed with CAP and was admitted to the hospital for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 31
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 7.4 mmol/L
Allergies: NKDA
Previous hospitalization: 1 month ago; received IV Abx for MRSA-associated CAP
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

IV Beta-lactams + PO macrolides/doxycycline + IV ceftazidime as standard regimen for at least 7 days (subjected to step-down Tx)

IV Beta-lactams:

1) Amoxicillin/clavulanate 1.2g q8h or
2) Ceftriaxone 1-2g q24h

and PO Macrolides/Doxycycline:

1) Azithromycin 500 mg OD or
2) Clarithromycin 500 mg BD or
3) Doxycycline 100mg BD

PLUS IV ceftazidime 2g q8h for specific coverage against Burkholderia pseudomallei

PLUS MRSA coverage:

1) IV Vancomycin 15mg/kg q8-12h OR
2) PO/IV Linezolid 600mg q12h

30
Q

Daptomycin is ineffective for pneumonia because it does not penetrate the lungs. True or false?

A

False! Daptomycin is ineffective for pneumonia because it is inactivated by pulmonary surfactants.

31
Q

A patient admitted to the hospital for community-acquired pneumonia (CAP) will require empiric MRSA coverage for CAP treatment if he/she has a history of MRSA cellulitis within the last 1 year. True or false?

A

False! Must be specific to respiratory MRSA pneumoniae in the last one year to consider additional MRSA coverage.

32
Q

A 62 y/o female with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. She was diagnosed with CAP and would be admitted to the hospital for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 32
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 7.2 mmol/L
Allergies: NKDA
Previous hospitalization: 6 months ago; received IV Abx for Pseudomonal CAP
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

IV Beta-lactams + PO macrolides/doxycycline + IV ceftazidime as standard regimen for at least 7 days (subjected to step-down Tx)

IV Beta-lactams:

1) Amoxicillin/clavulanate 1.2g q8h or
2) Ceftriaxone 1-2g q24h

and PO Macrolides/Doxycycline:

1) Azithromycin 500 mg OD or
2) Clarithromycin 500 mg BD or
3) Doxycycline 100mg BD

PLUS IV ceftazidime 2g q8h for specific coverage against Burkholderia pseudomallei & P. aeruginosa
- do NOT need additional anti-pseudomonal coverage on top of ceftazidime!!

33
Q

A 62 y/o female with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. She was diagnosed with CAP and would be admitted to the hospital for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 22
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 4.2 mmol/L
Allergies: NKDA
Previous hospitalization: 6 months ago; received IV Abx for Pseudomonal CAP
Chest XR: dense consolidation in the right lower lobe

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

IV Beta-lactams w/ anti-psuedomonal coverage + PO macrolides/doxycycline as standard regimen for at least 7 days (subjected to step-down Tx)

IV Beta-lactams w/ anti-pseudomonal coverage:

1) Piperacillin/tazobactam 4.5g q6-8h or
2) Cefepime 2g q8h or
3) Meropenem 1g q8h [if ESBL-producing strains are indicated]

and PO Macrolides/Doxycycline:

1) Azithromycin 500 mg OD or
2) Clarithromycin 500 mg BD or
3) Doxycycline 100mg BD

34
Q

Why are respiratory fluoroquinolones are NOT used as first-line therapy for CAP pt?

A
  • Increased adverse effects (e.g. tendonitis, tendon rupture, neuropathy, QTc prolongation, CNS disturbances, hypoglycemia)
  • Development of resistance with overuse (i.e. collateral damage)
  • Preserve activity for other gram-negative infections (esp. since FQ is the only PO options for anti-pseudomonal coverage)
  • Delay diagnosis of TB since respiratory FQ are active against M. tuberculosis & may result in partial Tx
35
Q

Corticosteroid therapy is routinely recommended as adjunctive Tx to systemic Abx for CAP pt. True or false?

A

False! Adjunctive corticosteroid therapy is NO longer recommended, as its clinical impact is small and likely outweighed by hyperglycemia.

36
Q

What are the therapeutic goals & monitoring parameters in the treatment of CAP?

A

Safety:

  • Adverse effects of Abx (e.g. diarrhea, rash)
  • Renal function/adjustment when required

Efficacy:

  • Clinical improvements expected in 48-72h (reduced cough, chest pain, SOB, fever, tachypnea & WBC etc.)
  • Should not escalate Abx Tx in first 72h (unless culture-directed or significant clinical deterioration)
  • Radiographic improvement lags behind for up to 4-6 weeks for resolution; repeat only if clinical deterioration
37
Q

When would empiric coverage for MRSA & Pseudomonas aeruginosa be stopped in the treatment of CAP?

A

May be stopped in 48h if no MRSA or P. aeruginosa is found on culture & pt is improving

38
Q

Under what conditions will PO step-down therapy be considered for CAP pt that was initially on IV Abx?

A

ALL must be met:

  • Hemodynamically stable (i.e. normal BP)
  • Clinically improved/improving
  • Afebrile >= 24h
  • Normally functioning GIT
  • Able to ingest PO medications
39
Q

How does one step-down Abx Tx for CAP pt from IV to PO?

A

Use susceptibility results to guide selection of PO Abx if there are positive cultures.

Otherwise (i.e. no positive cultures), use either the same Abx with PO formulation or another PO Abx from same Abx class.

40
Q

A 68 y/o male with PMH of T2DM presented to A&E with cough, chest pain, fever, and confusion x 2 days. He was diagnosed with CAP and would be admitted to the general medicine ward for treatment.

T 38.4 deg C, BP 126/86, HR 76, RR 22
Oxygen saturation 92% (room air)
WBC 11.8 x 10^9/L, urea 5.4 mmol/L
Allergies: no known drug allergies
Previous hospitalization: none
Chest XR: dense consolidation in the right lower lobe

Assume that he was started on amoxicillin/clavulanate (IV) + azithromycin (PO). Three days later, he is afebrile, vital signs and labs have normalized. He is tolerating PO diet. Recommend a step-down therapy for this patient.

A

Change amoxicillin/clavulanate from IV to PO 625mg TDS or 2g BD & maintain PO azithromycin 500mg OD for 2 more days.

41
Q

Why do we not treat CAP pt infected with Burkholderia pseudomallei empirically?

A

Tx duration lasts for at least 3-6 months on IV ceftazidime, thus will encourage development of resistance if B. pseudomallei is not present in the first place.

42
Q

What are some risk factors associated with nosocomial pneumonia?

A

Patient:
Elderly, smoking, COPD, cancer, immunosuppression, prolonged hospitalisation, coma, impaired consciousness, malnutrition

Infection Control:
Hand hygiene compliance & contaminated respiratory care devices

Healthcare:
Prior ABx use, sedatives, opioid analgesics, mechanical ventilation, supine position

43
Q

What are some preventive strategies adopted to minimise the risk of nosocomial pneumonia?

A

Practice consistent hand hygiene
Judicious use of Abx & medication with sedative effects

VAP-Specific:
Limit duration of mechanical ventilation
Minimise duration & deep levels of sedation
Elevate bed head by 30 degrees to minimise prolonged supine position

44
Q

Describe the microbiology of nosocomial pneumonia.

A

Compared to CAP, wider range & higher chance of MDROs (multi-drug resistant organisms)

Gram +ve: MSSA, MRSA, S. pneumoniae
Gram -ve: H. influenzae, E. coli, Proteus spp. Serratia marcescens, Enterobacter spp. Klebsiella pneumoniae (including MDR strains), Acinetobacter spp. (including MDR strains) & P. aeruginosa (including MDR strains)

45
Q

Briefly explain the principles of empiric Abx selection of nosocomial pneumonia.

A

Empirically MUST cover MSSA & P. aeruginosa
May require additional coverage (e.g. MRSA, other Gram-negatives) based on:
- MDRO risk factors
- Mortality risk factors
- Antibiogram (i.e. respective institution’s Abx susceptibility rates -> lower susceptibility -> higher resistance specific to Abx)

46
Q

What are the MDRO risk factors for HAP & VAP?

A

HAP: Prior Abx use w/in 90 days
VAP:
- Prior Abx use w/in 90 days
- Septic shock at time of VAP onset
- Acute respiratory distress syndrome (ARDS) preceding VAP onset
- >= 5 days of hospitalisation prior to VAP onset
- Acute renal replacement therapy (RRT) prior to VAP onset

47
Q

What are the mortality risk factors for HAP & VAP?

A

ONLY applies to HAP:

  • Requiring mechanical ventilation as a result of HAP
  • Septic shock
48
Q

Calculate the % of P. aeruginosa isolates that are resistant to piperacillin/tazobactam if the antibiogram indicates 88% susceptibility of P. aeruginosa to piperacillin/tazobactam.

A

12% of P. aeruginosa isolates are resistant to piperacillin/tazobactam.

49
Q

A 56 y/o female was intubated and admitted to ICU for close monitoring after her heart surgery. 3 days later, she developed a fever and displayed worsening oxygenation on mechanical ventilation.

T 38.4 deg C, BP 106/66, HR 96
WBC 17.8 x 10^9/L, SCr 86 umol/L
Allergies: NKDA
MRSA prevalence = 9%
P. aeruginosa: 92% susceptibility to piperacillin/tazobactam

Recommend an appropriate Abx regimen to treat the patient’s infection.

A

Backbone regimen: No MDRO & mortality risk factors + NO indication for MRSA coverage (i.e. min coverage)

Anti-pseudomonal beta-lactams:

1) Piperacillin/tazobactam IV 4.5g q6-8h or
2) Cefepime IV 2g q8h or
3) Meropenem IV 1g q8h (less preferred; reserved for ESBL-producing strains) or
4) Imipenem IV 500mg q6h (less preferred; reserved for ESBL-producing strains)

Tx Duration (including step-down Tx) = 7 days

50
Q

A 60 y/o female was intubated and admitted to ICU for close monitoring after her heart surgery. 3 days later, she developed a fever and displayed worsening oxygenation on mechanical ventilation.

T 38.4 deg C, BP 106/66, HR 96
WBC 17.8 x 10^9/L, SCr 86 umol/L
Allergies: penicillin (hives)
MRSA prevalence = 9%
P. aeruginosa: 92% susceptibility to piperacillin/tazobactam

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

Backbone regimen: No MDRO & mortality risk factors + NO indication for MRSA coverage (i.e. min coverage)

Anti-psuedomnoal fluoroquinolones (for severe penicillin allergy ONLY):
Levofloxacin IV 750mg q24h

NO moxifloxacin since lack anti-pseudomonal coverage.
NO ciprofloxacin since lack gram-positive S. pneumoniae & S. aureus coverage

Tx Duration (including step-down Tx) = 7 days

51
Q

A 60 y/o male was admitted to the hospital for close monitoring after his heart surgery. 3 days later, he was diagnosed with HAP.

T 38.4 deg C, BP 106/66, HR 96
WBC 17.8 x 10^9/L, SCr 86 umol/L
Allergies: NKDA
MRSA prevalence = 9%
P. aeruginosa: 89% susceptibility to piperacillin/tazobactam

Recommend an appropriate Abx regimen to treat the patient’s infection.

A

Backbone regimen: No MDRO & mortality risk factors + NO indication for MRSA coverage (i.e. min coverage)

Anti-pseudomonal beta-lactams:

1) Piperacillin/tazobactam IV 4.5g q6-8h or
2) Cefepime IV 2g q8h or
3) Meropenem IV 1g q8h (less preferred; reserved for ESBL-producing strains) or
4) Imipenem IV 500mg q6h (less preferred; reserved for ESBL-producing strains)

Tx Duration (including step-down Tx) = 7 days

52
Q

What are some indications for additional MRSA coverage for pt with HAP?

If MRSA coverage is indicated for these patients, what are the recommended Abx to be added to the backbone regimen?

A

1) MDRO risk factor: Prior Abx use w/in 90 days
2) Mortality risk factors: Mechanical ventilation as a result of HAP, septic shock
3) MRSA prevalence > 20% or unknown

If indicated, add vancomycin IV 15mg/kg q8-12h OR linezolid IV 600mg q12h to backbone regimen.

53
Q

What are some indications for additional gram-negative coverage for pt with HAP?

If additional gram-negative coverage is indicated for these patients, what are the recommended Abx to be added to the backbone regimen?

A

1) MDRO risk factor: Prior Abx use w/in 90 days
2) Mortality risk factors: Mechanical ventilation as a result of HAP, septic shock

If indicated, add either of the following (ensure different drug class) to backbone regimen:

1) Gentamicin IV 5-7 mg/kg q24h or
2) Amikacin IV 15 mg/kg q24h or
3) Tobramycin IV
4) Ciprofloxacin IV 400mg q8-12h
5) Levofloxacin IV 750mg q24h

54
Q

What are some indications for additional MRSA coverage for pt with VAP?

If MRSA coverage is indicated for these patients, what are the recommended Abx to be added to the backbone regimen?

A

1) MDRO risk factor:
- Prior Abx use w/in 90 days
- Septic shock at time of VAP onset
- ARDS preceding VAP onset
- >= 5 days of hospitalisation prior to VAP onset
- Acute RRT prior to VAP onset
2) MRSA prevalence > 10-20% or unknown

If indicated, add vancomycin IV 15mg/kg q8-12h OR linezolid IV 600mg q12h to backbone regimen.

55
Q

What are some indications for additional gram-negative coverage for pt with VAP?

If additional gram-negative coverage is indicated for these patients, what are the recommended Abx to be added to the backbone regimen?

A

1) MDRO risk factor:
- Prior Abx use w/in 90 days
- Septic shock at time of VAP onset
- ARDS preceding VAP onset
- >= 5 days of hospitalisation prior to VAP onset
- Acute RRT prior to VAP onset
2) Single anti-pseudomonal agent with activity < 90% or unknown

If indicated, add either of the following (ensure different drug class) to backbone regimen:

1) Gentamicin IV 5-7 mg/kg q24h or
2) Amikacin IV 15 mg/kg q24h or
3) Tobramycin IV
4) Ciprofloxacin IV 400mg q8-12h
5) Levofloxacin IV 750mg q24h

56
Q

A 58 y/o male was intubated and admitted to ICU for close monitoring after his heart surgery. 6 days later, he developed a fever and displayed worsening oxygenation on mechanical ventilation.

T 38.4 deg C, BP 106/66, HR 96
WBC 17.8 x 10^9/L, SCr 86 umol/L
Allergies: NKDA
MRSA prevalence = 9%
P. aeruginosa: 89% susceptibility to piperacillin/tazobactam

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

1) IV piperacillin/tazobactam 4.5g q6-8h +
2) IV vancomycin 15 mg/kg q8-12h +
3) IV amikacin 15 mg/kg q24h OR IV gentamicin 5-7 mg/kg q24h

Tx Duration (including step-down Tx) = 7 days

1 MDRO risk factor (>= 5 days hospitalisation) indicates for additional MRSA & gram-negative coverage, in addition to < 90% activity of piperacillin-tazobactam to P. aeruginosa.

57
Q

Explain the rationale for additional Gram-negative coverage, when indicated, for pt with nosocomial pneumonia.

A

Double gram-negative/pseudomonal coverage to empirically broaden spectrum of gram-negative coverage in patients at risk for MDRO or death, in the event one agent does not provide adequate coverage.

A different drug class is added on to backbone regiment to minimise risk of cross-resistance against a single anti-pseudomonal agent.

58
Q

Under what conditions can we de-escalate Tx therapy for pt diagnosed with nosocomial pneumonia?

A

1) Clinically improvement (expected in 72h)
- i.e. reduced cough, chest pain, SOB, fever, WBC, tachypnea, oxygen requirement etc
- elderly pt and/or those w/ multiple comorbidities may take longer
AND
2) Positive cultures w/ documented susceptibility OR negative blood & respiratory cultures

59
Q

How does one de-escalate Abx Tx for pt diagnosed with nosocomial pneumonia?

A

1) Positive blood and/or respiratory culture:
- Maintain coverage for organisms grown
2) Negative blood and/or respiratory culture:
- Maintain backbone regimen for MSSA & P. aeruginosa coverage

60
Q

A 58 y/o male was intubated and admitted to ICU for close monitoring after his heart surgery. 6 days later, he developed a fever and displayed worsening oxygenation on mechanical ventilation.

T 38.4 deg C, BP 106/66, HR 96
WBC 17.8 x 10^9/L, SCr 86 umol/L
Allergies: NKDA
MRSA prevalence = 9%
P. aeruginosa: 89% susceptibility to piperacillin/tazobactam

Assume that he was started on IV piperacillin/tazobactam + IV vancomycin + IV amikacin. Three days later, he is afebrile, vital signs and labs have normalized. Negative blood and respiratory cultures were reported as well. Recommend a step-down therapy for this patient.

A

IV piperacillin/tazobactam 4.5g q6-8h for another 4 more days.

61
Q

A 58 y/o male was intubated and admitted to ICU for close monitoring after his heart surgery. 3 days later, he developed a fever and displayed worsening oxygenation on mechanical ventilation.

T 38.4 deg C, BP 106/66, HR 96
WBC 17.8 x 10^9/L, SCr 86 umol/L
Allergies: NKDA
MRSA prevalence = 9%
P. aeruginosa: 89% susceptibility to piperacillin/tazobactam

Recommend the most appropriate Abx regimen to treat the patient’s infection.

A

1) IV piperacillin/tazobactam 4.5g q6-8h +
2) IV amikacin 15 mg/kg q24h OR IV gentamicin 5-7 mg/kg q24h

Tx Duration (including step-down Tx) = 7 days

Zero MDRO risk factor (< 5 days hospitalisation) means no additional MRSA coverage required

However, 89% < 90% activity of piperacillin-tazobactam to P. aeruginosa indicates additional gram-negative coverage.